Literature DB >> 20725814

A case of aggressive myeloma recognized shortly after the remission following high-dose chemotherapy with autologous peripheral blood stem cell transplantation.

Kaname Ueda1, Katsuhiro Miura, Yoshihiro Hatta, Sumiko Kobayashi, Toshitake Tanaka, Atsuko Hojo, Hikaru Ishizuka, Umihiko Sawada, Yoshimasa Kura, Jin Takeuchi.   

Abstract

A 45-year-old woman was referred to our hospital with acute renal failure and pyrexia. In August 2005, the patient was diagnosed with IgA-λ type multiple myeloma with chromosome 13 deletion, and received three cycles of vinclistine, adriamycin and dexamethasone followed by high-dose melphalan-based autologous peripheral stem cell transplantation: this resulted in remission 2 months before admission to our hospital. Serum IgA concentration was within the normal limit, but an excess of myeloma cells in bone marrow was confirmed. Immunoelectrophoresis revealed BJP-λ production with no IgA-λ. The patient received several courses of chemotherapy with mechanical ventilation and regular hemodialysis. The progression of the illness was rapid: multiple organ failure promptly developed and the patient died 2 months after admission. Autopsy revealed deposition of light chain λ protein in multiple organs. We report this unusual case of aggressive myeloma recognized shortly after successful autologous transplantation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20725814     DOI: 10.1007/s12185-010-0665-y

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  16 in total

1.  Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome.

Authors:  Hervé Avet-Loiseau; Michel Attal; Philippe Moreau; Catherine Charbonnel; Frédéric Garban; Cyrille Hulin; Serge Leyvraz; Mauricette Michallet; Ibrahim Yakoub-Agha; Laurent Garderet; Gérald Marit; Lucienne Michaux; Laurent Voillat; Marc Renaud; Bernard Grosbois; Gaelle Guillerm; Lotfi Benboubker; Mathieu Monconduit; Catherine Thieblemont; Philippe Casassus; Denis Caillot; Anne-Marie Stoppa; Jean-Jacques Sotto; Marc Wetterwald; Charles Dumontet; Jean-Gabriel Fuzibet; Isabelle Azais; Véronique Dorvaux; Marc Zandecki; Régis Bataille; Stéphane Minvielle; Jean-Luc Harousseau; Thierry Facon; Claire Mathiot
Journal:  Blood       Date:  2007-01-05       Impact factor: 22.113

2.  Maintenance therapy with thalidomide improves survival in patients with multiple myeloma.

Authors:  Michel Attal; Jean-Luc Harousseau; Serge Leyvraz; Chantal Doyen; Cyrille Hulin; Lofti Benboubker; Ibrahim Yakoub Agha; Jean-Henri Bourhis; Laurent Garderet; Brigitte Pegourie; Charles Dumontet; Marc Renaud; Laurent Voillat; Christian Berthou; Gerald Marit; Mathieu Monconduit; Denis Caillot; Bernard Grobois; Herve Avet-Loiseau; Philippe Moreau; Thierry Facon
Journal:  Blood       Date:  2006-07-27       Impact factor: 22.113

3.  Maintenance with pamidronate following first-line MP or VAD therapy in multiple myeloma.

Authors:  Haruki Kondo; Akinori Mori; Michio Kubota
Journal:  Leuk Lymphoma       Date:  2003-02

Review 4.  Aggressive phase multiple myeloma: a terminal anaplastic transformation resembling high-grade lymphoma.

Authors:  S L Allen; M Coleman
Journal:  Cancer Invest       Date:  1990       Impact factor: 2.176

5.  A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1.

Authors:  John D Shaughnessy; Fenghuang Zhan; Bart E Burington; Yongsheng Huang; Simona Colla; Ichiro Hanamura; James P Stewart; Bob Kordsmeier; Christopher Randolph; David R Williams; Yan Xiao; Hongwei Xu; Joshua Epstein; Elias Anaissie; Somashekar G Krishna; Michele Cottler-Fox; Klaus Hollmig; Abid Mohiuddin; Mauricio Pineda-Roman; Guido Tricot; Frits van Rhee; Jeffrey Sawyer; Yazan Alsayed; Ronald Walker; Maurizio Zangari; John Crowley; Bart Barlogie
Journal:  Blood       Date:  2006-11-14       Impact factor: 22.113

6.  Aggressive plasma cell myeloma. A terminal phase.

Authors:  A L Suchman; M Coleman; J A Mouradian; D J Wolf; S Saletan
Journal:  Arch Intern Med       Date:  1981-09

7.  Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.

Authors:  Jonathan J Keats; Rafael Fonseca; Marta Chesi; Roelandt Schop; Angela Baker; Wee-Joo Chng; Scott Van Wier; Rodger Tiedemann; Chang-Xin Shi; Michael Sebag; Esteban Braggio; Travis Henry; Yuan-Xiao Zhu; Homer Fogle; Tammy Price-Troska; Gregory Ahmann; Catherine Mancini; Leslie A Brents; Shaji Kumar; Philip Greipp; Angela Dispenzieri; Barb Bryant; George Mulligan; Laurakay Bruhn; Michael Barrett; Riccardo Valdez; Jeff Trent; A Keith Stewart; John Carpten; P Leif Bergsagel
Journal:  Cancer Cell       Date:  2007-08       Impact factor: 31.743

8.  High-dose melphalan-based autotransplants for multiple myeloma: the Arkansas experience since 1989 in 3077 patients.

Authors:  Mauricio Pineda-Roman; Bart Barlogie; Elias Anaissie; Maurizio Zangari; Vanessa Bolejack; Frits van Rhee; Guido Tricot; John Crowley
Journal:  Cancer       Date:  2008-04-15       Impact factor: 6.860

9.  Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma.

Authors:  Athanasios B-T Fassas; Tray Spencer; Jeffrey Sawyer; Maurizio Zangari; Choon-Kee Lee; Elias Anaissie; Firas Muwalla; Christopher Morris; Bart Barlogie; Guido Tricot
Journal:  Br J Haematol       Date:  2002-09       Impact factor: 6.998

10.  Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling.

Authors:  Jeffrey Haessler; John D Shaughnessy; Fenghuang Zhan; John Crowley; Joshua Epstein; Frits van Rhee; Elias Anaissie; Mauricio Pineda-Roman; Maurizio Zangari; Klaus Hollmig; Abid Mohiuddin; Yazan Alsayed; Antje Hoering; Guido Tricot; Bart Barlogie
Journal:  Clin Cancer Res       Date:  2007-12-01       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.